Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Hepatitis CHepatitis
- First Posted Date
- 2004-07-28
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 315
- Registration Number
- NCT00088504
- Locations
- 🇺🇸
Joseph L. Cochran, M.D., Birmingham, Alabama, United States
🇺🇸Suresh Karne, M.D., Ph.D., Huntsville, Alabama, United States
🇺🇸Vijayan Balan, M.D., Phoenix, Arizona, United States
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT00003847
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States